Kelly Maloney
Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 40 | 2025 | 293 | 5.620 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2025 | 86 | 1.660 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 18 | 2026 | 1938 | 1.250 |
Why?
| | Down Syndrome | 6 | 2023 | 523 | 1.230 |
Why?
| | Burkitt Lymphoma | 3 | 2024 | 63 | 0.930 |
Why?
| | Leukemia, Myeloid, Acute | 7 | 2026 | 674 | 0.880 |
Why?
| | Asparaginase | 8 | 2020 | 30 | 0.840 |
Why?
| | Fishes | 1 | 2024 | 110 | 0.810 |
Why?
| | Agriculture | 1 | 2024 | 102 | 0.790 |
Why?
| | Child | 74 | 2026 | 22440 | 0.740 |
Why?
| | Bayes Theorem | 1 | 2024 | 427 | 0.720 |
Why?
| | Consolidation Chemotherapy | 2 | 2019 | 10 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2025 | 1123 | 0.620 |
Why?
| | Child, Preschool | 49 | 2026 | 11630 | 0.610 |
Why?
| | Ecosystem | 1 | 2024 | 585 | 0.580 |
Why?
| | Disease-Free Survival | 12 | 2024 | 767 | 0.550 |
Why?
| | Leukemia | 4 | 2021 | 246 | 0.540 |
Why?
| | Oncogene Proteins, Fusion | 6 | 2024 | 210 | 0.530 |
Why?
| | Mercaptopurine | 5 | 2017 | 15 | 0.510 |
Why?
| | Prognosis | 17 | 2026 | 4210 | 0.510 |
Why?
| | Infant | 36 | 2026 | 9885 | 0.460 |
Why?
| | Recurrence | 12 | 2025 | 1122 | 0.460 |
Why?
| | Antineoplastic Agents | 7 | 2019 | 2220 | 0.460 |
Why?
| | Preleukemia | 1 | 2015 | 2 | 0.450 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 128 | 0.440 |
Why?
| | Drug Hypersensitivity | 3 | 2017 | 92 | 0.430 |
Why?
| | Molecular Targeted Therapy | 3 | 2021 | 440 | 0.420 |
Why?
| | Leukemia, Monocytic, Acute | 1 | 2014 | 3 | 0.420 |
Why?
| | Sarcoma, Myeloid | 1 | 2014 | 4 | 0.420 |
Why?
| | Neoplasm, Residual | 7 | 2023 | 135 | 0.400 |
Why?
| | Adolescent | 42 | 2026 | 22233 | 0.400 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 294 | 0.380 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 26 | 0.370 |
Why?
| | Erwinia | 2 | 2020 | 3 | 0.360 |
Why?
| | Medical Oncology | 5 | 2025 | 327 | 0.360 |
Why?
| | Humans | 86 | 2026 | 143821 | 0.350 |
Why?
| | Tumor Suppressor Proteins | 3 | 1999 | 324 | 0.350 |
Why?
| | Chromosome Aberrations | 2 | 2022 | 164 | 0.350 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 848 | 0.340 |
Why?
| | Neutropenia | 2 | 2022 | 155 | 0.340 |
Why?
| | Male | 58 | 2026 | 71569 | 0.330 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2019 | 681 | 0.330 |
Why?
| | Stem Cell Transplantation | 3 | 2019 | 190 | 0.320 |
Why?
| | Rhabdomyosarcoma | 1 | 2011 | 63 | 0.320 |
Why?
| | Cell Cycle Proteins | 3 | 1999 | 636 | 0.310 |
Why?
| | Carrier Proteins | 3 | 1999 | 750 | 0.310 |
Why?
| | Sarcoma, Ewing | 1 | 2011 | 101 | 0.310 |
Why?
| | Biomarkers, Tumor | 3 | 2026 | 1327 | 0.300 |
Why?
| | Ploidies | 2 | 2019 | 20 | 0.300 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 193 | 0.290 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 31 | 0.290 |
Why?
| | Genes, Tumor Suppressor | 2 | 1999 | 90 | 0.280 |
Why?
| | Catheter-Related Infections | 2 | 2022 | 93 | 0.280 |
Why?
| | Survival Rate | 8 | 2024 | 2034 | 0.280 |
Why?
| | Cyclophosphamide | 4 | 2019 | 267 | 0.280 |
Why?
| | Female | 56 | 2026 | 77570 | 0.280 |
Why?
| | Catheterization, Central Venous | 2 | 2022 | 120 | 0.270 |
Why?
| | Philadelphia Chromosome | 2 | 2018 | 18 | 0.270 |
Why?
| | Medication Adherence | 3 | 2017 | 519 | 0.260 |
Why?
| | Gene Deletion | 2 | 1998 | 388 | 0.240 |
Why?
| | Vincristine | 4 | 2021 | 138 | 0.240 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 443 | 0.230 |
Why?
| | Trisomy | 2 | 2021 | 78 | 0.230 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2017 | 107 | 0.230 |
Why?
| | Etoposide | 2 | 2019 | 166 | 0.230 |
Why?
| | Ikaros Transcription Factor | 1 | 2025 | 24 | 0.220 |
Why?
| | Young Adult | 15 | 2024 | 13914 | 0.210 |
Why?
| | Maryland | 1 | 2024 | 63 | 0.210 |
Why?
| | Invertebrates | 1 | 2024 | 24 | 0.210 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 89 | 0.210 |
Why?
| | Rivers | 1 | 2024 | 67 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2023 | 11459 | 0.200 |
Why?
| | PAX5 Transcription Factor | 2 | 2024 | 14 | 0.200 |
Why?
| | Anxiety | 3 | 2016 | 1100 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2025 | 2167 | 0.190 |
Why?
| | Genomics | 4 | 2025 | 834 | 0.190 |
Why?
| | Gene Rearrangement | 3 | 2019 | 156 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 78 | 0.180 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 4 | 0.180 |
Why?
| | Polyethylene Glycols | 5 | 2020 | 638 | 0.180 |
Why?
| | Induction Chemotherapy | 2 | 2019 | 86 | 0.180 |
Why?
| | Health Equity | 1 | 2024 | 119 | 0.180 |
Why?
| | Central Venous Catheters | 1 | 2022 | 53 | 0.170 |
Why?
| | Environmental Monitoring | 1 | 2024 | 377 | 0.170 |
Why?
| | Prednisone | 2 | 2019 | 223 | 0.170 |
Why?
| | Program Evaluation | 2 | 2017 | 947 | 0.170 |
Why?
| | Lymphoma | 1 | 2023 | 234 | 0.170 |
Why?
| | Doxorubicin | 2 | 2022 | 395 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2636 | 0.160 |
Why?
| | Adult | 23 | 2023 | 40129 | 0.160 |
Why?
| | Translocation, Genetic | 2 | 2013 | 115 | 0.160 |
Why?
| | Maintenance Chemotherapy | 2 | 2017 | 42 | 0.160 |
Why?
| | Bacterial Infections | 1 | 2022 | 247 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 201 | 0.150 |
Why?
| | Diploidy | 1 | 2019 | 16 | 0.150 |
Why?
| | Risk Factors | 11 | 2022 | 10623 | 0.150 |
Why?
| | Genes, p16 | 1 | 1999 | 13 | 0.150 |
Why?
| | Hyperglycemia | 1 | 2023 | 370 | 0.140 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 1998 | 27 | 0.140 |
Why?
| | Quality of Life | 3 | 2024 | 3142 | 0.140 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1998 | 55 | 0.140 |
Why?
| | Myelodysplastic Syndromes | 1 | 2020 | 143 | 0.140 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 64 | 0.140 |
Why?
| | Rituximab | 1 | 2019 | 210 | 0.140 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1998 | 76 | 0.140 |
Why?
| | Prospective Studies | 9 | 2022 | 7900 | 0.140 |
Why?
| | Mutagenesis | 1 | 1999 | 191 | 0.140 |
Why?
| | Prostate-Specific Antigen | 2 | 2009 | 158 | 0.140 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2020 | 184 | 0.130 |
Why?
| | Patient Safety | 1 | 2021 | 338 | 0.130 |
Why?
| | Proto-Oncogenes | 1 | 1997 | 29 | 0.130 |
Why?
| | Family Relations | 2 | 2016 | 94 | 0.130 |
Why?
| | Thioguanine | 1 | 2017 | 18 | 0.130 |
Why?
| | Thionucleotides | 1 | 2017 | 35 | 0.130 |
Why?
| | Apyrase | 1 | 2017 | 27 | 0.130 |
Why?
| | Oncologists | 1 | 2017 | 46 | 0.130 |
Why?
| | Blast Crisis | 1 | 2016 | 35 | 0.120 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5316 | 0.120 |
Why?
| | Carboxypeptidases A | 1 | 2016 | 2 | 0.120 |
Why?
| | Pediatricians | 1 | 2017 | 122 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 273 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 639 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 500 | 0.120 |
Why?
| | Osteonecrosis | 1 | 2015 | 23 | 0.120 |
Why?
| | Retrospective Studies | 10 | 2023 | 16754 | 0.110 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.110 |
Why?
| | Mentors | 2 | 2017 | 214 | 0.110 |
Why?
| | Depression | 2 | 2016 | 1520 | 0.110 |
Why?
| | Cohort Studies | 6 | 2026 | 5861 | 0.110 |
Why?
| | Pancreatitis | 1 | 2016 | 135 | 0.110 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 172 | 0.110 |
Why?
| | Dexamethasone | 4 | 2021 | 373 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 291 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2016 | 69 | 0.110 |
Why?
| | Mentoring | 1 | 2017 | 162 | 0.110 |
Why?
| | Longitudinal Studies | 7 | 2016 | 2948 | 0.110 |
Why?
| | Mutation | 4 | 2022 | 4106 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 14 | 0.110 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 71 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 559 | 0.100 |
Why?
| | Bacteremia | 1 | 2016 | 220 | 0.100 |
Why?
| | Repressor Proteins | 1 | 1997 | 432 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2018 | 1192 | 0.100 |
Why?
| | Antigens, CD | 1 | 2017 | 564 | 0.100 |
Why?
| | Cross Infection | 1 | 2016 | 260 | 0.100 |
Why?
| | Pediatrics | 3 | 2021 | 1080 | 0.100 |
Why?
| | Life Change Events | 1 | 2014 | 146 | 0.100 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2013 | 42 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 1998 | 1493 | 0.100 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2010 | 140 | 0.100 |
Why?
| | Risk Assessment | 5 | 2026 | 3556 | 0.100 |
Why?
| | Immunotherapy | 1 | 2018 | 669 | 0.100 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 10 | 0.090 |
Why?
| | Transcription Factors | 2 | 1998 | 1735 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 330 | 0.090 |
Why?
| | Myeloproliferative Disorders | 1 | 2012 | 19 | 0.090 |
Why?
| | Karyotyping | 3 | 2019 | 107 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1268 | 0.090 |
Why?
| | Self Report | 1 | 2017 | 865 | 0.090 |
Why?
| | Contraindications | 1 | 2012 | 84 | 0.090 |
Why?
| | Arabinonucleosides | 1 | 2011 | 8 | 0.090 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 21 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2009 | 977 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1522 | 0.080 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2010 | 19 | 0.080 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2010 | 27 | 0.080 |
Why?
| | Pain | 1 | 2016 | 776 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1508 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 2041 | 0.070 |
Why?
| | Parents | 2 | 2016 | 1414 | 0.070 |
Why?
| | Age Factors | 8 | 2019 | 3288 | 0.070 |
Why?
| | Prostatectomy | 1 | 2009 | 89 | 0.070 |
Why?
| | Bloom Syndrome | 1 | 1988 | 3 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 704 | 0.070 |
Why?
| | Juxtaglomerular Apparatus | 1 | 2007 | 2 | 0.070 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2016 | 55 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1057 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 779 | 0.060 |
Why?
| | Blood Coagulation | 1 | 2008 | 272 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2026 | 118 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1047 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1147 | 0.060 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 6004 | 0.060 |
Why?
| | Animals | 3 | 2024 | 38140 | 0.060 |
Why?
| | Methotrexate | 2 | 2017 | 239 | 0.060 |
Why?
| | Remission Induction | 2 | 2019 | 307 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 996 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2024 | 3614 | 0.050 |
Why?
| | Selection Bias | 1 | 2024 | 38 | 0.050 |
Why?
| | Personal Satisfaction | 2 | 2017 | 221 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2845 | 0.050 |
Why?
| | Administration, Oral | 2 | 2017 | 841 | 0.050 |
Why?
| | Genetic Variation | 1 | 1988 | 990 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 410 | 0.050 |
Why?
| | Risk | 5 | 2023 | 901 | 0.050 |
Why?
| | Drug Monitoring | 2 | 2017 | 394 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2871 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 13 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1688 | 0.040 |
Why?
| | Exome | 1 | 2022 | 239 | 0.040 |
Why?
| | Drug Therapy | 1 | 2021 | 81 | 0.040 |
Why?
| | Menorrhagia | 1 | 2001 | 22 | 0.040 |
Why?
| | Transcriptome | 2 | 2019 | 1047 | 0.040 |
Why?
| | Diarrhea | 2 | 1999 | 188 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 303 | 0.040 |
Why?
| | Endocrine Glands | 1 | 1979 | 14 | 0.040 |
Why?
| | Blood Cell Count | 1 | 1999 | 53 | 0.040 |
Why?
| | Chromosomes, Human | 1 | 2019 | 44 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 154 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 1999 | 52 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 515 | 0.040 |
Why?
| | Genome-Wide Association Study | 2 | 2016 | 1446 | 0.040 |
Why?
| | Mosaicism | 1 | 2019 | 75 | 0.040 |
Why?
| | Sequence Deletion | 1 | 1999 | 194 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1239 | 0.040 |
Why?
| | Disinfectants | 1 | 1999 | 47 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2018 | 52 | 0.040 |
Why?
| | Chromosomes | 1 | 2019 | 107 | 0.030 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 272 | 0.030 |
Why?
| | Escherichia coli O157 | 1 | 1998 | 35 | 0.030 |
Why?
| | Infant, Newborn | 4 | 2019 | 6362 | 0.030 |
Why?
| | Methylation | 1 | 1998 | 243 | 0.030 |
Why?
| | Overweight | 1 | 2023 | 598 | 0.030 |
Why?
| | Biopsy | 1 | 2021 | 1068 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2021 | 884 | 0.030 |
Why?
| | Community Participation | 1 | 1999 | 134 | 0.030 |
Why?
| | United States | 4 | 2021 | 15602 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2407 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 21 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1041 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2017 | 83 | 0.030 |
Why?
| | Escherichia coli Infections | 1 | 1998 | 128 | 0.030 |
Why?
| | Food-Drug Interactions | 1 | 2017 | 11 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2017 | 135 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 56 | 0.030 |
Why?
| | Career Mobility | 1 | 2017 | 70 | 0.030 |
Why?
| | Leucovorin | 1 | 2017 | 100 | 0.030 |
Why?
| | Dairy Products | 1 | 2017 | 30 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 92 | 0.030 |
Why?
| | MEF2 Transcription Factors | 1 | 2016 | 51 | 0.030 |
Why?
| | Family | 1 | 2021 | 692 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 85 | 0.030 |
Why?
| | Water Purification | 1 | 1999 | 157 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 427 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2017 | 317 | 0.030 |
Why?
| | Luciferases | 1 | 2016 | 153 | 0.030 |
Why?
| | Methyltransferases | 1 | 2017 | 74 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2016 | 151 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1065 | 0.030 |
Why?
| | Sulfonamides | 1 | 2020 | 574 | 0.030 |
Why?
| | Ethers | 1 | 1996 | 19 | 0.030 |
Why?
| | Methyl Ethers | 1 | 1996 | 19 | 0.030 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2015 | 12 | 0.030 |
Why?
| | Fluorides | 1 | 1996 | 49 | 0.030 |
Why?
| | Hemorrhage | 1 | 2001 | 799 | 0.030 |
Why?
| | Cytarabine | 1 | 2016 | 66 | 0.030 |
Why?
| | Genotype | 3 | 2017 | 1837 | 0.030 |
Why?
| | Health Education | 1 | 1999 | 358 | 0.030 |
Why?
| | Anesthetics, Inhalation | 1 | 1996 | 51 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2926 | 0.030 |
Why?
| | Breast Neoplasms | 5 | 1979 | 2497 | 0.030 |
Why?
| | Spinal Dysraphism | 1 | 1996 | 107 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2016 | 219 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 639 | 0.030 |
Why?
| | Middle Aged | 10 | 2019 | 35630 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2017 | 243 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 1998 | 524 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 748 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 1999 | 1255 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 445 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 281 | 0.030 |
Why?
| | DNA Methylation | 1 | 1999 | 673 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1626 | 0.030 |
Why?
| | Psychomotor Agitation | 1 | 2014 | 45 | 0.030 |
Why?
| | Behavior | 1 | 2014 | 90 | 0.020 |
Why?
| | Demography | 1 | 2014 | 289 | 0.020 |
Why?
| | Income | 1 | 2014 | 197 | 0.020 |
Why?
| | Marriage | 1 | 2014 | 122 | 0.020 |
Why?
| | Algorithms | 1 | 2021 | 1843 | 0.020 |
Why?
| | Base Sequence | 1 | 2016 | 2186 | 0.020 |
Why?
| | Aged | 9 | 2019 | 25615 | 0.020 |
Why?
| | Blood Glucose | 1 | 2023 | 2325 | 0.020 |
Why?
| | Odds Ratio | 1 | 2015 | 1057 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 321 | 0.020 |
Why?
| | Aggression | 1 | 2014 | 179 | 0.020 |
Why?
| | Prevalence | 2 | 2016 | 2819 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2011 | 8 | 0.020 |
Why?
| | Kidney | 2 | 1996 | 1483 | 0.020 |
Why?
| | Regression Analysis | 1 | 2014 | 1003 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 70 | 0.020 |
Why?
| | Time Factors | 2 | 2015 | 7068 | 0.020 |
Why?
| | Erythrocytes | 1 | 2017 | 757 | 0.020 |
Why?
| | Escherichia coli | 1 | 2015 | 849 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 179 | 0.020 |
Why?
| | Mice | 2 | 2019 | 18421 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1358 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2095 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 888 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3073 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 957 | 0.020 |
Why?
| | Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1988 | 67 | 0.020 |
Why?
| | Cell Fusion | 1 | 1988 | 49 | 0.020 |
Why?
| | Emotions | 1 | 2014 | 575 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 85 | 0.020 |
Why?
| | Water Microbiology | 2 | 1999 | 88 | 0.020 |
Why?
| | Protein C | 1 | 2008 | 54 | 0.020 |
Why?
| | Antithrombins | 1 | 2008 | 70 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 6032 | 0.020 |
Why?
| | Genetic Markers | 1 | 1988 | 338 | 0.020 |
Why?
| | Fibrinogen | 1 | 2008 | 180 | 0.020 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 414 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 184 | 0.020 |
Why?
| | Rare Diseases | 1 | 2007 | 113 | 0.020 |
Why?
| | Blood Pressure Determination | 1 | 2007 | 141 | 0.020 |
Why?
| | Nephrectomy | 1 | 2007 | 156 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4248 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2847 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1733 | 0.010 |
Why?
| | Cell Line | 1 | 1988 | 2906 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 2001 | 2 | 0.010 |
Why?
| | Blood Platelet Disorders | 1 | 2001 | 10 | 0.010 |
Why?
| | von Willebrand Diseases | 1 | 2001 | 29 | 0.010 |
Why?
| | Estriol | 1 | 1979 | 6 | 0.010 |
Why?
| | Estrone | 1 | 1979 | 40 | 0.010 |
Why?
| | Menstruation | 1 | 1979 | 41 | 0.010 |
Why?
| | Prolactin | 1 | 1979 | 92 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2001 | 208 | 0.010 |
Why?
| | Bolivia | 1 | 1999 | 61 | 0.010 |
Why?
| | Luteinizing Hormone | 1 | 1979 | 191 | 0.010 |
Why?
| | Follicle Stimulating Hormone | 1 | 1979 | 250 | 0.010 |
Why?
| | Restaurants | 1 | 1998 | 22 | 0.010 |
Why?
| | Swimming | 1 | 1998 | 49 | 0.010 |
Why?
| | Food Handling | 1 | 1998 | 63 | 0.010 |
Why?
| | Progesterone | 1 | 1979 | 255 | 0.010 |
Why?
| | Disease Transmission, Infectious | 1 | 1998 | 68 | 0.010 |
Why?
| | Water Supply | 1 | 1998 | 88 | 0.010 |
Why?
| | Meat | 1 | 1998 | 92 | 0.010 |
Why?
| | Kyphosis | 1 | 1996 | 37 | 0.010 |
Why?
| | Halothane | 1 | 1996 | 7 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1308 | 0.010 |
Why?
| | Estradiol | 1 | 1979 | 538 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 1996 | 105 | 0.010 |
Why?
| | Population Surveillance | 1 | 1999 | 491 | 0.010 |
Why?
| | Feces | 1 | 1998 | 506 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 1996 | 334 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 1978 | 594 | 0.010 |
Why?
| | Pedigree | 3 | 1978 | 512 | 0.010 |
Why?
| | Nebraska | 2 | 1976 | 20 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 1999 | 8130 | 0.000 |
Why?
| | New York | 2 | 1976 | 125 | 0.000 |
Why?
| | Genes | 1 | 1978 | 226 | 0.000 |
Why?
| | Genetic Linkage | 1 | 1978 | 274 | 0.000 |
Why?
| | Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| | Apocrine Glands | 1 | 1976 | 4 | 0.000 |
Why?
| | Genetic Techniques | 1 | 1976 | 67 | 0.000 |
Why?
| | Pheochromocytoma | 1 | 1976 | 58 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1976 | 279 | 0.000 |
Why?
| | Syndrome | 1 | 1976 | 373 | 0.000 |
Why?
| | Klinefelter Syndrome | 1 | 1976 | 76 | 0.000 |
Why?
| | HLA Antigens | 1 | 1976 | 227 | 0.000 |
Why?
| | Skin Diseases | 1 | 1976 | 149 | 0.000 |
Why?
| | Abnormalities, Multiple | 1 | 1976 | 196 | 0.000 |
Why?
| | Pregnancy | 2 | 1978 | 7154 | 0.000 |
Why?
| | Sarcoma | 1 | 1976 | 203 | 0.000 |
Why?
| | Sex Factors | 1 | 1978 | 2078 | 0.000 |
Why?
| | Thyroid Neoplasms | 1 | 1976 | 346 | 0.000 |
Why?
| | Neoplasms | 2 | 1976 | 2902 | 0.000 |
Why?
| | Melanoma | 1 | 1976 | 806 | 0.000 |
Why?
| | Phenotype | 1 | 1976 | 3183 | 0.000 |
Why?
| | Registries | 1 | 1976 | 2242 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1976 | 1307 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|